Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares (NQ:LSE)

4.920 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 9, 2026 Add to My Watchlist

Price and Volume

Volume	0
Open	4.920
Bid (Size)	4.600 (1,800)
Ask (Size)	5.500 (300)
Prev. Close	4.920
Today's Range	4.920 - 4.920
52wk Range	3.800 - 9.780
Shares Outstanding	17,025,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

April 08, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre|CISION® exatecan peptide drug conjugate

March 31, 2026

From Avacta Group PLC

Via GlobeNewswire

Performance

YTD	+15.2%	+15.2%
1 Month	+4.3%	+4.3%
3 Month	+7.7%	+7.7%
6 Month	-10.7%	-10.7%
1 Year	-5.2%	-5.2%

More News

HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics

March 26, 2026

From HOOKIPA Pharma Inc.

Via GlobeNewswire

PPHC Added to Russell 2000® and Russell 3000® Indexes

March 24, 2026

From Public Policy Holding Company, Inc.

Via GlobeNewswire

Public Policy Holding Company, Inc. Announces Full Year 2025 Financial Results

March 23, 2026

From Public Policy Holding Company, Inc.

Via GlobeNewswire

PPHC Announces Acquisition of WPI Strategy

March 23, 2026

From Public Policy Holding Company, Inc.

Via GlobeNewswire

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

March 22, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

PPHC Expands Strategic Advisory Platform with Appointment of TrailRunner Sports President

March 18, 2026

From Public Policy Holding Company, Inc.

Via GlobeNewswire

Avacta Announces Preclinical and Translational Presentations of pre|CISION® Platform Candidates at the 2026 AACR Annual Conference

March 17, 2026

From Avacta Group PLC

Via GlobeNewswire

HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

March 09, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

Intended Retirement of Independent Non-executive Director and changes of composition of board committees

March 06, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

PPHC To Report Fourth Quarter and Full Year 2025 Financial Results on March 23, 2026

March 05, 2026

From Public Policy Holding Company, Inc.

Via GlobeNewswire

HUTCHMED Reports 2025 Full Year Results and Business Updates

March 05, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

March 04, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis

February 24, 2026

From Avacta Group PLC

Via GlobeNewswire

Leishen Energy Holding Co., Ltd. Announced Fiscal Year 2025 Financial Results Highlighting Strong Operating Cash Flow and Low Financial Leverage

February 15, 2026

From Leishen Energy Holding Co., Ltd.

Via GlobeNewswire

Corero Network Security to Present at the AI & Technology Virtual Investor Conference February 19th

February 13, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Avacta appoints Francis Wilson as Chief Scientific Officer

February 09, 2026

From Avacta Group PLC

Via GlobeNewswire

HUTCHMED to Announce 2025 Final Results

February 06, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics

February 03, 2026

From HOOKIPA Pharma Inc.

Via GlobeNewswire

Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program

February 03, 2026

From AVACTA GROUP PLC

Via GlobeNewswire

Interim Results for the six months ended 31 October 2025

January 29, 2026

From Scancell Holdings Plc

Via GlobeNewswire

Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma

January 26, 2026

From Scancell Holdings Plc

Via GlobeNewswire

Leishen Energy Holding Co., Ltd. Announces Receipt of Nasdaq Notice Regarding Annual Meeting Requirement

January 23, 2026

From Leishen Energy Holding Co., Ltd.

Via GlobeNewswire

Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)

January 21, 2026

From AVACTA GROUP PLC

Via GlobeNewswire

Frequently Asked Questions

Is Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares publicly traded?

Yes, Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares is publicly traded.

What exchange does Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares trade on?

Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares?

The ticker symbol for Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares is LSE on the Nasdaq Stock Market

What is the current price of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares?

The current price of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares is 4.920

When was Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares last traded?

The last trade of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares was at 04/09/26 04:00 PM ET

What is the market capitalization of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares?

The market capitalization of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares is 83.76M

How many shares of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares are outstanding?

Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares has 84M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.